• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Challenges to Equal Access in MS Treatment

Video

The Medicaid group exhibited higher rates of MS-related complications than did the commercial group, such as gait abnormalities (17.3% vs 10.4%); burning, numbness or tingling (21.9% vs 17.9%); dizziness/vertigo (14.6% vs 9.2%); and urinary incontinence (16.0% vs 5.8%; P < .001 for all). The Medicaid group also had a higher rate with nearly all comorbidities, such as hypertension (35.7% vs 30.2%), diabetes (16.6% vs 9.6%) and asthma (15.9% vs 6.0%; P < .001 for all). (19)

Related Videos
© 2024 MJH Life Sciences

All rights reserved.